AFFILIATIONS
1 Department of Pathology, Stanford University, Stanford, California, United States
2 Department of Pathology, Stanford University, Stanford, California, United States
3 Division of Hematology, Stanford University School of Medicine, Stanford, California, United States
4 Division of Hematology, Stanford University School of Medicine, Stanford, California, United States
5 Division of Hematology, Stanford University School of Medicine, Stanford, California, United States
6 Division of Hematology, Stanford University School of Medicine, Stanford, California, United States
7 Department of Pathology, Stanford University, Stanford, California, United States
8 TenSixteen Bio, San Francisco, California, United States
9 TenSixteen Bio, San Francisco, California, United States
10 Division of Hematology, Stanford University School of Medicine, Stanford, California, United States
11 Department of Pathology, Stanford University, Stanford, California, United States
12 Department of Pathology, Stanford University, Stanford, California, United States, Insititue for Stem Cell Biology & Regenerative Medicine, Stanford University, Stanford, California, United States
ABSTRACT
All blood cells arise from a common pool of hematopoietic stem cells (HSCs). Some HSCs acquire mutations which afford the capacity for clonal expansion at greater rates in the stem cell pool over non-mutated HSCs—this phenomenon describes a pre-malignant state for blood cancers termed clonal hematopoiesis of indeterminate potential (CHIP). Although CHIP is a pre-malignant state, it may also evolve into blood cancers, especially myeloid. Our group recently uncovered that the clonal expansion associated with CHIP is driven by de-repressed expression of the gene TCL1A in HSCs (Weinstock, Gopakumar et al., Nature 2023). Importantly, the TCL1A promoter is poorly conserved between mice and humans, suggesting existing mouse models of CHIP driver mutations do not fully recapitulate human CHIP due to lack of expression of the mouse homolog of TCL1A in these models.
To address this limitation of existing mouse models, and to better model how TCL1A expression in HSCs influences their phenotype, we developed a transgenic mouse model with huTCL1A conditionally expressed in HSCs and other hematopoietic cells using the Cre-Lox system (floxed huTCL1A mice crossed to Vav1 or Tal1-Cre mice). Phenotypically, 8–12-week-old huTCL1A mice exhibited a 2-fold increase in hematopoietic stem and progenitor cell (HSPC) populations, including long-term (LT) HSCs. huTCL1A also led to increased expansion of LT-HSCs ex vivo compared to Cre littermate controls, suggesting a TCL1A-dependent cell-intrinsic effect on LT-HSCs. Consistent with these observations, in vivo administration of BrDU revealed increased cycling in huTCL1A HSPCs. Monthly blood count analysis revealed hematological parameters were largely similar between groups and within normal limits for the first six months of life.
A previously described mouse model in which huTCL1A expression is limited to B cells develops mature lymphoid malignancies resembling human chronic lymphocytic leukemia with splenomegaly and high circulating lymphoid counts at 13-18 months of age (Bichi et al., PNAS 2002). Strikingly, huTCL1A mice with pan-hematopoietic (including HSC) TCL1A expression died at 7-12 months of age with 100% penetrance of a disease characterized by pancytopenia, marked hepatomegaly, and lack of lymphocytosis, whereas no littermate Cre controls became sick (n=15/genotype , p-value =0.001). Flow cytometry analysis from moribund huTCL1A mice displayed a massively expanded Lin-, cKitlo, Sca1+, CD34+, CD11b+, MPO+ myeloid population variably present in marrow, spleen, or liver which was confirmed by immunohistochemistry. Single-cell RNA-seq analysis on marrow from a moribund huTCL1A mouse confirmed the myeloid nature of the malignancy. Some of the moribund mice also had expanded clonal mature B cell populations in addition to the abnormal myeloid cells, but this was in a minority of cases. To confirm that the neoplasm derived from huTCL1A were transplantable, bone marrow from a healthy control or a moribund huTCL1A mouse with an expanded population as described above were transplanted into lethally irradiated mice. By 6 months, all moribund huTCL1Amarrow recipient mice died, whereas no healthy control marrow recipients died.
Mechanistically, we assessed the effect TCL1A may have on apoptotic pathways in HSCs utilizing Staurosporine, a known inducer of apoptosis through caspase-3/9 activation. Following in vivo challenge with Staurosporine, HSPCs from 3-month-old huTCL1A mice exhibited nearly 4-fold fewer apoptotic cells compared to Cre controls as determined by flow cytometry, suggesting TCL1A expression disrupts apoptotic signaling in HSCs.
In conclusion, the development of myeloid neoplasm in huTCL1A mice suggests that TCL1A expression acts not just as a promoter of HSC clonal expansion, but also as an oncogenic switch. These findings position aberrant TCL1A expression in HSCs as an important component of CHIP progression to myeloid malignancies.
DISCLOSURES
Isak William Tengesdal, PhD: Olatec Therapeutics - Current equity holder in private company